Development Focus Areas

Stuart Therapeutics has selected a series of development and technology partnering opportunities that best utilize PolyCol’s unique characteristics. PolyCol’s ability to rapidly repair the damaged collagen present in dry eye disease, coupled with the concurrent recovery of the corneal epithelium and reduction of inflammation, make this the company’s primary focus through ST-100. We see numerous ocular surface indication label expansion opportunities for this therapeutic, including Allergic Conjunctivitis, Corneal Trauma, and Corneal Ulcers. The development of ST-100 is supported by compelling animal testing results, with complete healing of damaged corneal tissues in 24 hours or less.
Other variants of the PolyCol platform have demonstrated promise in two major diseases with significant unmet need: Glaucoma and Dry Age-Related Macular Degeneration (Dry AMD). Stuart has completed in vitro testing that shows PolyCol as an effective tool to both repair damaged supporting membranes in these disease states, and to encourage functional cell recovery. These results suggest a new path in treating these chronic indications. Finally, Stuart has completed in vivo testing that suggests that certain PolyCol variants may effectively penetrate via drop mode of administration to the retina, opening additional opportunities for the platform.

Dry Eye Disease

For Keratitis Sicca, or chronic dry eye, Stuart Therapeutics is taking advantage of PolyCol’s rapid tissue repair capability to directly address the causal tissue damage that results in inflammation for this indication. The ST-100 drug candidate is expected to provide quick relief for ocular surface damage caused by the condition, healing damaged corneal and conjunctival tissues, with patient relief expected in 24 to 48 hours, compared with several weeks for competing alternatives.

Dry Eye Disease Phase 2

Glaucoma

For glaucoma, a PolyCol variant administered via drop formulation penetrates through the inner limiting membrane, and acts to heal damage caused by glaucoma to the collagen extra-cellular matrix supporting the optic nerve as it enters the body of the eye. This repair acts to protect the nerve cells, and encourages nerve cell recovery.

Glaucoma IND-Enabling

Dry Age-Related Macular Degeneration

For Dry AMD, a PolyCol variant administered via drop formulation penetrates through the inner limiting membrane, and, acts to rapidly repair damage to Bruch’s membrane, providing a healthy environment for retinal pigment epithelial cell proliferation and adherence.

Dry AMD